Effect of epicatechin gallate dietary supplementation on transgenic drosophila model of parkinson's disease

Journal of Dietary Supplements

Volumn 11, Issue 2, 2014, Pages 121-130

  Siddique, Yasir Hasan ^a   Jyoti, Smita ^a   Naz, Falaq ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Alpha synuclein; Drosophila; Epicatechin gallate; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; ANTIOXIDANT; CATECHIN; DROSOPHILA PROTEIN; EPICATECHIN GALLATE; PLANT EXTRACT; SNCA PROTEIN, HUMAN;

ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; BRAIN; CAMELLIA SINENSIS; CHEMISTRY; CYTOLOGY; DIET SUPPLEMENTATION; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DROSOPHILA MELANOGASTER; DRUG EFFECTS; HUMAN; LIPID PEROXIDATION; LOCOMOTION; METABOLISM; OXIDATIVE STRESS; PARKINSON DISEASE; PHYTOTHERAPY; TRANSGENIC ANIMAL;

ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIOXIDANTS; APOPTOSIS; BRAIN; CAMELLIA SINENSIS; CATECHIN; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; HUMANS; LIPID PEROXIDATION; LOCOMOTION; OXIDATIVE STRESS; PARKINSON DISEASE; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 84896990853     PISSN: 19390211     EISSN: 1939022X     Source Type: Journal    
DOI: 10.3109/19390211.2013.859207     Document Type: Article

References (41)

1. Abbott RA, Cox M, Markus H, Tomkins A. Diet, body size and micronutrient status in Parkinson's disease. Eur J Clin Nutr. 1992;46:879-884.
2. Abrans JM, White K, Fessler LI, Steller H. Programmed cell death during Drosophila embryogenesis. Development. 1993;117:29-43.
3. Auluck PK, Bonini NM. Pharmacological prevention of Parkinson disease in Drosophila. Nat Med. 2002;8:1185-1186.
4. Auluck PK, Meulener MC, Bonini NM.Mechanisms of suppression of {alpha}-synuclein neurotoxicity by geldanamycin in Drosophila. J Biol Chem. 2005;280:2873-2878.
5. Benford DJ, Hanley AB, Bottrill K, Oehlschlager S, Balls M, Branca F, Castegnaro JJ, Descotes J, Hemminiki K, Lindsay D, Schilter B. Biomarkers as predictive tools in toxicity testing. The report and recommendations of EVCAM Workshop 40. Alt Lab Anim. 2000;28:119-131.
6. Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, Wanker EE. EGCG remodels mature alpha synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci. USA. 2010;107:7710-7715.
7. Butterfield DA, Kanski J. Brain protein oxidation in age related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev. 2001;15:945-962.
8. Caruana M, Högen T, Levin J, Hillmer A, Giese A, Vassallo N. Inhibition and disaggregation of alpha Synuclein oligomers by natural polyphenolic compounds. FEBS Lett. 2011;585:1113 1120.
9. Celotto AM, Palladino MJ. Drosophila A "model" model system to study neurodegeneration. Mol Inter. 2005;5:292-303.
10. Conway KA, Rochet JC, Bieganski RM, Lansbury PT. Kinetic stabilization of the alphasynuclein protofibril by a dopamine-alpha-synuclein adduct. Science. 2001; 249: 1346-1349.
11. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909.
12. Duffy JB. GAL4 system in Drosophila: a fly geneticist's Swiss army knife. Genesis 2002;32:1-15.
13. Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, Maraganore D,Gwinn-Hardy K, Wszolek Z, Dickson D, Langston JW. Comparsion of kindreds with Parkinsonisms and alpha synuclein genomic multiplication. Ann Neurol. 2004;55:174-179.
14. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature. 2000;404:394-398.
15. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. Alpha synuclein is phosphorylated in synucleinopathy lesions. Nat cell Biol. 2002;4:160-164.
16. Festing MFW, Baumans V, Combes DR, Halder M, Hendricsen FM, Howard BR, Lovell DP, Moore GJ, Overend P, Wilson MS. Reducing the use of laboratory animals in biomedical research: problems and possible solutions. Alt Lab Anim. 1998;26:283-301.
17. Galvin JE, Giasson B, Hurtig HI, Lee VM, Trojanowski JQ. Neurodegeneration with brain iron accumulation type I is characterized by alpha, beta and gamma synuclein neuropathology. Am J Pathol. 2000;157:361-368.
18. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synuclein pathy lesions. Science. 2000;290:985-989.
19. Khan S, Jyoti S, Naz F, Shakya B, Rahul, Afzal M, Siddique YH. Effect of L-ascorbic acid on the climbing ability and protein levels in the brain of Drosophila model of Parkinson's disease. Int J Neuro Sci. 2012;122:704-709.
20. Lees AJ, Hardy J, Revesz T. "Parkinson's Disease". Lancet. 2009;373:2055-2066.
21. Long J, Gao H, Sun L, Liu J, Zhao-Wilson Xi. Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends life span in a Drosophila Parkison's disease model. Rejuv Res. 2009;12:321-331.
22. Lorenz M, Urban J. Green and black tea are equally potent stimuli of no production and vasodilation: New insights in tea ingredients involved. Basic Res Cardiol. 2009;104:100-110.
23. Lü JM, Nurko J, Weakley SM, Jiang J, Kougias P, Lin PH, Yao Q, Chen C. Molecularmechanisms and clinical application of nordihydroguaiaretic acid (NDGA) and its derivatives: an update. Med Sci Monit. 2010;16: RA 93-R 100.
24. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L. Dopaminergic loss and inclusion body formation in alpha Synuclein mice: implication for neurodegenerative disorders. Science. 2000;287:1265-1269.
25. Mitchell KJ, Staveley BE. Protocol for the detection and analysis of cell death in the adult Drosophila brain. Dros Inf Serv. 2006;93:118-121.
26. Muñoz-Soriano V, Paricio N. Drosophila models of Parkinson's disease: discovering relevant pathways and novel therapeutic strategies. Parkinson's Dis. 2011;14. doi:10.4061/2011/520640
27. Naoi M, Maruyama W. Future of neuroprotection in Parkinson's disease. Parkinson Relat Disord. 2001;8:139-145.
28. Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril- destabilizing effects for alpha synuclein fibrils in vitro. J Neurochem. 2006;97:105-115.
29. Pal R, Miranda M, Narayan M. Nitrosative stress-induced Parkinsonian lewy like aggregates prevented through polyphenolic phytochemical analog intervention. Biochem Biophys Res Commun. 2011;404:324-329.
30. Pendleton RG, Parvez F, Sayed M, Hillman R. Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster. J Pharmacol Exp Therap. 2002;300:91-96.
31. Prasad KN, Cole WC,KumarB.Multiple antioxidants in the prevention and treatment of Parkinson's Disease. J Am Coll Nutr. 1999;18:413-423.
32. Reiter LT, Potocki L, Chien S, Gribskov M, Bier E. A systematic analysis of human diseaseassociated gene sequences in Drosophila melanogaster. Genome Res. 2001;11:1114-1125.
33. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ. The formation of highly soluble oligomers of alpha synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron. 2003;37:583-595.
34. Siddique YH, Ara G, Afzal M, Faisal M. Protective role of Plumbago zeylanica extract against toxic effects of ethinylestradiol in the third instar larvae of transgenic Drosophila melanogaster (hsp70-lacZ)Bg9 and cultured human peripheral blood lymphocytes. Alt Med Stud. 2011;7:26-29.
35. Siddique YH, Ara G, Afzal M. Estimation of lipid peroxidation induced by hydrogen peroxide in cultured human lymphocytes. Dose Res. 2012;10:1-10.
36. Siddique YH, Ara G, Jyoti S, Afzal M. Protective effect of curcumin in transgenic Drosophila melanogaster model of Parkinson's disease in Drosophila melanogaster. Alt Med Stud. 2012;2e3:7-9.
37. Siddique YH, Ara G, Jyoti S, Afzal M. Effect of Capsaicin on the climbing ability in Drosophila model of Parkinson's disease. Am J Drug Dis Dev. 2012;2:50-54.
38. Siddique YH,Ara G, Jyoti S,Afzal M. The dietary supplementation of nordihydroguaiaretic acid (NDGA) delayed the loss of climbing ability in Drosophila model of Parkinson's disease. J Diet Suppl. 2012;9:1-8.
39. Vander Putten H, Wiederhold KH, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WP, Ruegg MA, Lin S, Caroni P, Sommer B, Tolnay M, Bilbe G. Neuropathology in mice expressing human alpha-synuclein. J Neurosci. 2000;15:6021-6029.
40. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA. 1994;91:8324-8328.
41. Zhang Y, Dawson VL, Dawson TM. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis. 2000;7:240-250.